BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19451361)

  • 1. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
    Buja LM
    Circulation; 2009 May; 119(19):2539-41. PubMed ID: 19451361
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and treatment of renal involvement in Fabry disease.
    Branton M; Schiffmann R; Kopp JB
    J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S139-43. PubMed ID: 12068026
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
    Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
    Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
    Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
    J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry nephropathy and the case for adjunctive renal therapy.
    Wanner C; Breunig F
    J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
    [No Abstract]   [Full Text] [Related]  

  • 8. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fabry disease - complex clinical picture, simple diagnosis procedure, causal treatment].
    Hoffmann B; Beck M; Rolfs A; Neumann HP
    Dtsch Med Wochenschr; 2008 Sep; 133(39):1965-72; quiz 1973-4. PubMed ID: 18798134
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal pathology in Fabry disease.
    Alroy J; Sabnis S; Kopp JB
    J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S134-8. PubMed ID: 12068025
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
    Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
    Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for Fabry's disease.
    Gahl WA
    N Engl J Med; 2001 Jul; 345(1):55-7. PubMed ID: 11439950
    [No Abstract]   [Full Text] [Related]  

  • 16. Histologic and electron microscopy findings in myocardium of treated Fabry disease.
    Owens CL; Russell SD; Halushka MK
    Hum Pathol; 2006 Jun; 37(6):764-8. PubMed ID: 16733219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
    Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
    Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uveitis and Fabry disease.
    Elstein D; Altarescu G; Zimran A
    Eye (Lond); 2007 Mar; 21(3):448; author reply 448-9. PubMed ID: 17024216
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fabry disease: Pathogenesis, pathophysiology, and therapy].
    Utsumi K
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():537-40. PubMed ID: 16523950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.